Our team’s mission is to help our customers unlock single-cell biology to enable the discovery, development, and delivery of better precision medicines. We serve researchers, clinicians, and drug developers who are making the world healthier and we are honored to support their work to better the lives of patients in need.
This month, Genome Research published a peer-reviewed study validating the technology that powers our Tapestri Platform. The study marks the first-ever application of a commercial high throughput single-cell DNA sequencing technology to patient samples. Together, MD Anderson Cancer Center and Mission Bio deployed Tapestri to resolve tumor heterogeneity at the single-cell DNA level, at the speed and scale needed for routine use.